Telix Pharmaceuticals Ltd — Capital/Financing Update 2020

Dec 2, 2020

Telix Pharmaceuticals Limited ACN 616 620 369 Suite 401, 55 Flemington Road North Melbourne Victoria, 3051 Australia

==> picture [146 x 81] intentionally omitted <==

Telix and DuChemBio Announce Korean Partnership for Advanced Prostate Cancer Imaging

Melbourne (Australia) and Seoul (South Korea) – 3[rd] December 2020 . Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has entered into a commercialisation and partnership agreement with DuChemBio Co, Ltd. (DuChemBio), the leading South Korean radiopharmaceutical company, for Telix’s prostate cancer imaging product TLX591-CDx ([68] GaPSMA-11).

DuChemBio has the largest radiopharmaceutical manufacturing network serving the field of Nuclear Medicine in Korea. Telix has granted exclusive rights to DuChemBio to commercialise TLX591-CDx for prostate cancer imaging in South Korea. The parties will cooperate to attain a marketing authorisation for the product from the Korean Ministry of Food and Drug Safety (MFDS).

DuChemBio CEO Jongwoo Kim stated “Through the years, DuChemBio has contributed to the diagnosis and treatment of patients in Korea across a range of therapy areas, commencing in 2012 with the introduction of Korea's first new radiopharmaceutical, FP-CIT for the diagnosis of Parkinson's disease. Now, we look forward to introducing Telix’s state-of-the-art PSMA imaging to the Korean market for men with prostate cancer. We believe there is growing demand for PSMA imaging across the prostate cancer disease spectrum in Korea, and we are pleased to partner with Telix to be one of the first markets in Asia to offer PSMA imaging to patients in need.”

Telix Pharmaceuticals CEO Christian Behrenbruch stated “Telix’s mission is to be a leading global oncology company and South Korea is a key Asian market for our products. We are pleased to have entered this commercialisation and partnership agreement with DuChemBio to bring this highly anticipated product to Korean men with prostate cancer. DuChemBio has a well-deserved reputation as the number one radiopharmaceutical company in Korea and we look forward to exploring future commercial and clinical opportunities through the experience of this initial partnership.”

About TLX591-CDx

TLX591-CDx (kit for the preparation of[68] Ga-PSMA-11) is a proprietary formulation of PSMA-HBEDCC (PSMA-11), a novel small molecule agent targeting prostate-specific membrane antigen (PSMA), originally developed by the Heidelberg group of the Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ).[1] The ‘cold kit’ format of TLX591-CDx enables rapid radiolabelling at room temperature with high radiochemical purity and production consistency, ideally suited for the radiopharmacy setting.[2]

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

1 Eder, et al. Bioconjugate Chem Apr 18, 2012; 23(4): 688-97. 2 TLX591-CDx has not received a marketing authorisation in any jurisdiction.

Page 1

About DuChemBio

Established in 2002, DuChemBio is the largest radiopharmaceutical firm and the undisputed leader in the field of oncology and neurology PET imaging tracers in South Korea. As a pioneer of a fully integrated nuclear diagnostics business model, DuChemBio develops, manufactures, and commercializes radiopharmaceutical tracers for PET/CT and PET/MRI hybrid imaging. The company operates seven radiopharmacy facilities across the country, and is closely collaborating with leading hospitals and research centers in Seoul to develop and advance the field of Nuclear Medicine in South Korea. DuChemBio has successfully launched novel proprietary radiopharmaceutical products both developed locally and licensed from international partners. DuChemBio has been advised by BGM Associates GmbH, a Berlin-based strategy and transactions advisory firm focused on healthcare and life science industries.

Telix Corporate Contact Dr Christian Behrenbruch Telix Pharmaceuticals Limited CEO Email: chris@telixpharma.com

Telix Investor Relations Dr David N. Cade Telix Pharmaceuticals Limited CBO and Head of Investor Relations Email: david.cade@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “U.S. Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.

Page 2